bevacizumab,atezolizumab,gemcitabine
roche
[]
phase 2 imbrave151 results presented at #gi23 demonstrated potential clinical benefit in a subset of patients with abtc. could azeto + bev + cisgem be the new 1l tx for this population? stay informed with updates from #noeticinsight! 